A higher dose of anti-CD19 CAR-T resulted in similar toxicities, but higher ORR and longer PFS, compared with a lower dose in patients with relapsed/refractory CLL.
Andrea S. Blevins Primeau, PhD, MBA
Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.